Objective. To understanding the molecular mechanisms in invasion andmetastasis of the ovarian carcinoma, we investigate a novel candidate metastasis―associated gene (MTA1) and nm23Hl mRNA expression and mutation in o...Objective. To understanding the molecular mechanisms in invasion andmetastasis of the ovarian carcinoma, we investigate a novel candidate metastasis―associated gene (MTA1) and nm23Hl mRNA expression and mutation in ovarian carcinoma. Methods. Twenty primary ovariancarcinoma specimens, 20 corresponding lymph nodes and 8 normal ovarian was examined for mRNAexpression and mutation of MTA1 and nm23Hl genes by reverse-transcription ploymerase chain reaction(RT―PCR) and RT―PCR―SSCP analysis. The level of the expression was determined by the relativeoptic desity (ROD) of the PCR products. Results. The frequency of MAT1 overexpression was 100% (7/7)in primary ovarian carcinoma with metastasis but only 38.5% (5/13) in those without metastasis(P=0.0103). Overexpression of MAT1 was observed in 87.5% (6/7) of lymph nodes with metastasis butonly 23% (3/13). of lymph nodes without metastasis (P=0.0118). In contrast with MAT1, low expressionof nm23H1 mRNA was seen in 7 of 7 o-varian carcinoma with metastasis but only in 4 of 13(30%) ofthose without metastassis (P=0.0043). Low nm23H1 expression was also seen in 7 of 7 lymph nodes withmetastasis but only in 5 of 13 (38.5%) nonmetastatic lymph nodes (P=0.0102). The ROD ratio of MAT1to nm23Hl increased with the development of metastasis. No mutation of MAT1 and nm23H1 genes wasfound by SSCP analysis. Conclusion. The mRNA expression of MTA1 and nm23H1 is positively andnegatively correlated with lymph node metastasis, respectively. Expression abnormalities but notmutation of the two genes are frequent events related to lymph node metastasis of ovarian cancer.展开更多
Ovarian cancer is the fifth lethal gynecologic malignancy. Metastasis-associated gene 1 （MTA1） is overexpressed in many malignant tumors with high metastatic potential. This study investi- gated whether down-regulat...Ovarian cancer is the fifth lethal gynecologic malignancy. Metastasis-associated gene 1 （MTA1） is overexpressed in many malignant tumors with high metastatic potential. This study investi- gated whether down-regulation of MTA1 expression by RNAi in A2780 ovarian cancer cells could affect proliferation, anoikis, migration, invasion and adhesion of the cells and to research the potential for MTA1 gene therapy of ovarian cancer. After transfection with effective Mtal gene siRNA, the effects on proliferation, anoikis, migration, invasion and adhesion of A2780 cells were tested by MTT assay, flow cytometry, wound-healing assay, Transwell assay and adhesion assay. Expression levels of PTEN, beta 1 integrin, MMP-9, phosphor-AKT （Ser473）, and total AKT activity were evaluated in control and transfected cells. The results showed that inhibition of MTA1 mediated by Mtal-siRNA transfection decreased the cell invasion, migration and adhesion, and induced the increased cell anoikis, but no significant difference was found in proliferation of A2780 cancer cells. In addition, beta 1 integrin, MMP-9, and phosphor-AKT protein levels were significantly down-regulated, while PTEN was significantly up-regulated. These results demonstrated that MTA1 played an important role in the cell metastasis in ovarian cancer. MTA1 could serve as another novel potential therapeutic target in ovarian cancer.展开更多
目的检测转移相关基因1（MTAl）蛋白在小细胞肺癌（SCLC）组织中的表达情况，探讨其在SCLC转移、预后和化疗敏感性预测中的作用。方法采用免疫组织化学法检测52例无远处转移SCLC组织标本中MTAl的表达，根据免疫组化结果分为两类：低表...目的检测转移相关基因1（MTAl）蛋白在小细胞肺癌（SCLC）组织中的表达情况，探讨其在SCLC转移、预后和化疗敏感性预测中的作用。方法采用免疫组织化学法检测52例无远处转移SCLC组织标本中MTAl的表达，根据免疫组化结果分为两类：低表达（≤6分）和高表达（〉6分）；分析MTAl表达水平与临床病理特征、EP方案（足叶乙甙100mg／in。静滴，d1-d5；顺铂60mg／m2静滴，d1，3周为1周期，共4-6个周期）化疗疗效及预后的关系。结果52例SCLC组织中MTAl高表达率为71．2％（37／52），18例癌旁组织均为低表达（100．0％）；MTAl表达在不同肿瘤直径、TNM分期、淋巴结转移与否和有无脉管侵犯之间的差异有统计学意义（P〈0．05），而在性别、年龄、VALG分期及肿瘤部位之间的差异无统计学意义（P〉0．05）；MTAl高表达组的EP方案化疗敏感率低于MTAl低表达组（54．1％ vs.80．0％，P=0．020）；MTAl低表达组的中位无进展生存期和总生存期均优于MTAl高表达组（20个月狐8个月，33个月 vs 35．18个月），差异有统计学意义（P〈0．05）。结论MTAl在SCLC组织中高表达，且与肿瘤转移、耐药及预后密切相关。展开更多
目的检测转移相关基因1(MTA1)在膀胱癌组织中的表达水平以及其对患者预后的影响。方法应用Western blot方法以及实时定量PCR法检测MTA1在7例膀胱癌组织及对应癌旁组织的表达情况,并应用免疫组织化学法验证MTA1在116例膀胱癌组织及癌旁...目的检测转移相关基因1(MTA1)在膀胱癌组织中的表达水平以及其对患者预后的影响。方法应用Western blot方法以及实时定量PCR法检测MTA1在7例膀胱癌组织及对应癌旁组织的表达情况,并应用免疫组织化学法验证MTA1在116例膀胱癌组织及癌旁组织的表达水平,分析其表达水平与患者年龄、肿瘤大小、T分期、淋巴结转移、淋巴管浸润等临床病例资料之间的关系,探讨MTA1对患者预后的影响。结果 Western blot和PCR证实在蛋白及mRNA水平MTA1在膀胱癌组织表达水平均高于其对应的癌旁组织(蛋白水平P=0.006,mRNA水平P=0.002)。免疫组化显示,MTA1在膀胱癌中的阳性率为63.79%,与患者的淋巴结转移(P=0.035)、淋巴管浸润(P=0.001)有关,而与患者的年龄、肿瘤大小、T分期等没有统计学意义;高表达MTA1的患者5年生存率显著低于无或低表达的患者(P=0.012);MTA1的表达是患者预后的独立因素。结论MTA1在膀胱癌中的表达水平显著高于癌旁组织,其表达水平影响患者的预后,可能在膀胱癌的转移过程中发挥关键作用,提示MTA1可作为膀胱癌预测、治疗的新靶点。展开更多
文摘Objective. To understanding the molecular mechanisms in invasion andmetastasis of the ovarian carcinoma, we investigate a novel candidate metastasis―associated gene (MTA1) and nm23Hl mRNA expression and mutation in ovarian carcinoma. Methods. Twenty primary ovariancarcinoma specimens, 20 corresponding lymph nodes and 8 normal ovarian was examined for mRNAexpression and mutation of MTA1 and nm23Hl genes by reverse-transcription ploymerase chain reaction(RT―PCR) and RT―PCR―SSCP analysis. The level of the expression was determined by the relativeoptic desity (ROD) of the PCR products. Results. The frequency of MAT1 overexpression was 100% (7/7)in primary ovarian carcinoma with metastasis but only 38.5% (5/13) in those without metastasis(P=0.0103). Overexpression of MAT1 was observed in 87.5% (6/7) of lymph nodes with metastasis butonly 23% (3/13). of lymph nodes without metastasis (P=0.0118). In contrast with MAT1, low expressionof nm23H1 mRNA was seen in 7 of 7 o-varian carcinoma with metastasis but only in 4 of 13(30%) ofthose without metastassis (P=0.0043). Low nm23H1 expression was also seen in 7 of 7 lymph nodes withmetastasis but only in 5 of 13 (38.5%) nonmetastatic lymph nodes (P=0.0102). The ROD ratio of MAT1to nm23Hl increased with the development of metastasis. No mutation of MAT1 and nm23H1 genes wasfound by SSCP analysis. Conclusion. The mRNA expression of MTA1 and nm23H1 is positively andnegatively correlated with lymph node metastasis, respectively. Expression abnormalities but notmutation of the two genes are frequent events related to lymph node metastasis of ovarian cancer.
基金supported by the youth innovation fundation of the First Affiliated Hospital of Zhengzhou University
文摘Ovarian cancer is the fifth lethal gynecologic malignancy. Metastasis-associated gene 1 （MTA1） is overexpressed in many malignant tumors with high metastatic potential. This study investi- gated whether down-regulation of MTA1 expression by RNAi in A2780 ovarian cancer cells could affect proliferation, anoikis, migration, invasion and adhesion of the cells and to research the potential for MTA1 gene therapy of ovarian cancer. After transfection with effective Mtal gene siRNA, the effects on proliferation, anoikis, migration, invasion and adhesion of A2780 cells were tested by MTT assay, flow cytometry, wound-healing assay, Transwell assay and adhesion assay. Expression levels of PTEN, beta 1 integrin, MMP-9, phosphor-AKT （Ser473）, and total AKT activity were evaluated in control and transfected cells. The results showed that inhibition of MTA1 mediated by Mtal-siRNA transfection decreased the cell invasion, migration and adhesion, and induced the increased cell anoikis, but no significant difference was found in proliferation of A2780 cancer cells. In addition, beta 1 integrin, MMP-9, and phosphor-AKT protein levels were significantly down-regulated, while PTEN was significantly up-regulated. These results demonstrated that MTA1 played an important role in the cell metastasis in ovarian cancer. MTA1 could serve as another novel potential therapeutic target in ovarian cancer.
文摘目的检测转移相关基因1（MTAl）蛋白在小细胞肺癌（SCLC）组织中的表达情况，探讨其在SCLC转移、预后和化疗敏感性预测中的作用。方法采用免疫组织化学法检测52例无远处转移SCLC组织标本中MTAl的表达，根据免疫组化结果分为两类：低表达（≤6分）和高表达（〉6分）；分析MTAl表达水平与临床病理特征、EP方案（足叶乙甙100mg／in。静滴，d1-d5；顺铂60mg／m2静滴，d1，3周为1周期，共4-6个周期）化疗疗效及预后的关系。结果52例SCLC组织中MTAl高表达率为71．2％（37／52），18例癌旁组织均为低表达（100．0％）；MTAl表达在不同肿瘤直径、TNM分期、淋巴结转移与否和有无脉管侵犯之间的差异有统计学意义（P〈0．05），而在性别、年龄、VALG分期及肿瘤部位之间的差异无统计学意义（P〉0．05）；MTAl高表达组的EP方案化疗敏感率低于MTAl低表达组（54．1％ vs.80．0％，P=0．020）；MTAl低表达组的中位无进展生存期和总生存期均优于MTAl高表达组（20个月狐8个月，33个月 vs 35．18个月），差异有统计学意义（P〈0．05）。结论MTAl在SCLC组织中高表达，且与肿瘤转移、耐药及预后密切相关。
文摘目的检测转移相关基因1(MTA1)在膀胱癌组织中的表达水平以及其对患者预后的影响。方法应用Western blot方法以及实时定量PCR法检测MTA1在7例膀胱癌组织及对应癌旁组织的表达情况,并应用免疫组织化学法验证MTA1在116例膀胱癌组织及癌旁组织的表达水平,分析其表达水平与患者年龄、肿瘤大小、T分期、淋巴结转移、淋巴管浸润等临床病例资料之间的关系,探讨MTA1对患者预后的影响。结果 Western blot和PCR证实在蛋白及mRNA水平MTA1在膀胱癌组织表达水平均高于其对应的癌旁组织(蛋白水平P=0.006,mRNA水平P=0.002)。免疫组化显示,MTA1在膀胱癌中的阳性率为63.79%,与患者的淋巴结转移(P=0.035)、淋巴管浸润(P=0.001)有关,而与患者的年龄、肿瘤大小、T分期等没有统计学意义;高表达MTA1的患者5年生存率显著低于无或低表达的患者(P=0.012);MTA1的表达是患者预后的独立因素。结论MTA1在膀胱癌中的表达水平显著高于癌旁组织,其表达水平影响患者的预后,可能在膀胱癌的转移过程中发挥关键作用,提示MTA1可作为膀胱癌预测、治疗的新靶点。
